Pathogenesis and Treatment of Chronic Hyperuricemic Nephropathy

作者: 孟晓璐 , 杨宝学 , 周 虹 :北京大学医学部基础医学院药理学系,天然药物及仿生药物国家重点实验室,北京; 李 欣 :青岛大学附属医院,山东 青岛;

关键词: 痛风高尿酸血症慢性肾脏疾病药物治疗Gout Hyperuricemia Chronic Kidney Diseases (CKD) Medical Treatment

近年来大规模流行病学研究发现,高尿酸血症与高血压、心脑血管疾病、糖尿病、代谢综合征等疾病的发生和发展密切相关,已成为威胁人类健康的严重代谢性疾病,也是肾脏疾病进展的独立危险因素。尿酸作为嘌呤代谢的终末产物,可以通过多种分子机制导致肾脏损伤,包括诱导炎症反应和肾脏间质纤维化,激活氧化应激,诱导肾小管上皮细胞向间质细胞转化(epithelial-to-mesenchymal transition, EMT)等。为了深入研究高尿酸血症性肾脏疾病的发病机制,寻找新的药物治疗靶点,本文对高尿酸血症性肾病发生发展的病理生理机制及其治疗药物的研究进展进行综述。

Abstract: Large numbers of epidemiological and clinical studies in recent years have accumulated that hyperuricemia may be strongly linked with many metabolic diseases, including hypertension, cardiac-cerebral vascular disease, diabetes and metabolic syndrome. It has been regarded as a severe disease threatening human health and an independent risk factor in the progression of kidney diseases as well. As the end product of purine metabolism, uric acid can induce renal injury through multiple mechanisms, such as inflammation, renal fibrosis, oxidative stress and epithelial-to-mesenchymal transition. To further study the pathogenesis of hyperuricemia nephropathy and potential targets involved, we mainly discuss the physiopathologic mechanism and medical treatment of hyperuricemia in this review.

文章引用: 孟晓璐 , 李 欣 , 杨宝学 , 周 虹 (2016) 高尿酸血症性肾病的发病机制及药物治疗。 生理学研究, 4, 1-9. doi: 10.12677/JPS.2016.41001


[1] Sugahara, S., Ueda, Y., Fukuhara, K., Kamamuta, Y., Matsuda, Y., Murata, T., et al. (2015) Antioxidant Effects of Herbal Tea Leaves from Yacon (Smallanthus sonchifolius) on Multiple Free Radical and Reducing Power Assays, Especially on Different Superoxide Anion Radical Generation Systems. Journal of Food Science, 80, C2420-C2429. http://dx.doi.org/10.1111/1750-3841.13092

[2] Sen, S., De, B., Devanna, N. and Chakraborty, R. (2013) Total Phenolic, Total Flavonoid Content, and Antioxidant Capacity of the Leaves of Meyna spinosa Roxb., an Indian Medicinal Plant. Chinese Journal of Natural Medicines, 11, 149-157. http://dx.doi.org/10.1016/S1875-5364(13)60042-4

[3] Ryu, E.S., Kim, M.J., Shin, H.S., Jang, Y.H., Choi, H.S., Jo, I., et al. (2013) Uric Acid-Induced Phenotypic Transition of Renal Tubular Cells as a Novel Mechanism of Chronic Kidney Disease. American Journal of Physiology. Renal Physiology, 304, F471-F480. http://dx.doi.org/10.1152/ajprenal.00560.2012

[4] Dave, N., Guaita-Esteruelas, S., Gutarra, S., Frias, A., Beltran, M., Peiro, S., et al. (2011) Functional Cooperation between Snail1 and Twist in the Regulation of ZEB1 Expression during Epithelial to Mesenchymal Transition. The Journal of Biological Chemistry, 286, 12024-12032. http://dx.doi.org/10.1074/jbc.M110.168625

[5] Stamp, L.K., Merriman, T.R., Barclay, M.L., Singh, J.A., Roberts, R.L., Wright, D.F., et al. (2014) Impaired Response or Insufficient Dosage? Examining the Potential Causes of “Inadequate Response” to Allopurinol in the Treatment of Gout. Seminars in Arthritis and Rheumatism, 44, 170-174. http://dx.doi.org/10.1016/j.semarthrit.2014.05.007

[6] Thurston, M.M., Phillips, B.B. and Bourg, C.A. (2013) Safety and Efficacy of Allopurinol in Chronic Kidney Disease. The Annals of Pharmacotherapy, 47, 1507-1516. http://dx.doi.org/10.1177/1060028013504740

[7] Lam, M.P., Yeung, C.K. and Cheung, B.M. (2013) Pharmacogenetics of Allopurinol—Making an Old Drug Safer. Journal of Clinical Pharmacology, 53, 675-679. http://dx.doi.org/10.1002/jcph.67

[8] Hosoya, T., Kimura, K., Itoh, S., Inaba, M., Uchida, S., Tomino, Y., et al. (2014) The Effect of Febuxostat to Prevent a Further Reduction in Renal Function of Patients with Hyperuricemia Who Have Never Had Gout and Are Complicated by Chronic Kidney Disease Stage 3: Study Protocol for a Multicenter Randomized Controlled Study. Trials, 15, 26. http://dx.doi.org/10.1186/1745-6215-15-26

[9] Garcia-Valladares, I., Khan, T. and Espinoza, L.R. (2011) Efficacy and Safety of Febuxostat in Patients with Hyperuricemia and Gout. Therapeutic Advances in Musculoskeletal Disease, 3, 245-253. http://dx.doi.org/10.1177/1759720X11416405

[10] Frampton, J.E. (2015) Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout. Drugs, 75, 427-438. http://dx.doi.org/10.1007/s40265-015-0360-7

[11] Gray, C.L. and Walters-Smith, N.E. (2011) Febuxostat for Treatment of Chronic Gout. American Journal of Health- System Pharmacy, 68, 389-398. http://dx.doi.org/10.2146/ajhp100394

[12] Sircar, D., Chatterjee, S., Waikhom, R., Golay, V., Raychaudhury, A., Chatterjee, S., et al. (2015) Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double- Blind, Randomized, Placebo-Controlled Trial. American Journal of Kidney Diseases, 66, 945-950. http://dx.doi.org/10.1053/j.ajkd.2015.05.017

[13] Xu, S., Liu, X., Ming, J., Chen, S., Wang, Y., Liu, X., et al. (2015) A Phase 3, Multicenter, Randomized, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Chinese Gout Patients with Hyperuricemia. International Journal of Rheumatic Diseases, 18, 669-678. http://dx.doi.org/10.1111/1756-185X.12648

[14] Chen, S., Zhang, T., Wang, J., Wang, F., Niu, H., Wu, C., et al. (2015) Synthesis and Evaluation of 1-Hydroxy/me- thoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic Acid Derivatives as Non-Purine Xanthine Oxidase Inhibitors. European Journal of Medicinal Chemistry, 103, 343-353. http://dx.doi.org/10.1016/j.ejmech.2015.08.056

[15] Yoon, S., Shin, D., Lee, H., Jang, I.J. and Yu, K.S. (2015) Pharmacokinetics, Pharmacodynamics, and Tolerability of LC350189, a Novel Xanthine Oxidase Inhibitor, in Healthy Subjects. Drug Design, Development and Therapy, 9, 5033- 5049. http://dx.doi.org/10.2147/DDDT.S86884

[16] Zafar, H., Saad, S.M., Perveen, S., Arshia, Malik, R., Khan, A., et al. (2015) 2-Arylquinazolin-4(3H)-ones: Inhibitory Activities against Xanthine Oxidase. Medicinal Chemistry, 12, 54-62. http://dx.doi.org/10.2174/1573406410666150807111336

[17] Jansen, T.L. (2015) Rational Pharmacotherapy (RPT) in Goutology: Define the Serum Uric Acid Target & Treat-to- Target Patient Cohort and Review on Urate Lowering Therapy (ULT) Applying Synthetic Drugs. Joint Bone Spine, 82, 225-229. http://dx.doi.org/10.1016/j.jbspin.2014.02.015

[18] Chen, G., Tan, M.L., Li, K.K., Leung, P.C. and Ko, C.H. (2015) Green Tea Polyphenols Decreases Uric Acid Level through Xanthine Oxidase and Renal Urate Transporters in Hyperuricemic Mice. Journal of Ethnopharmacology, 175, 14-20. http://dx.doi.org/10.1016/j.jep.2015.08.043

[19] Chen, W.J., Wu, Y., Xu, C., Liu, S., Wang, W.Z., Song, F.R., et al. (2015) [Study on Therapeutic Effects of Ermiao Pill and Ermiao Pill Categorized Formula in Hyperuricemic Rats Using Spectroscopic Methods]. Spectroscopy and Spectral Analysis, 35, 956-960.

[20] Mazzali, M., Hughes, J., Kim, Y.G., Jefferson, J.A., Kang, D.H., Gordon, K.L., et al. (2001) Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism. Hypertension, 38, 1101-1106. http://dx.doi.org/10.1161/hy1101.092839

[21] Stevens, P.E. and Levin, A. (2013) Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. Annals of Internal Medicine, 158, 825-830. http://dx.doi.org/10.7326/0003-4819-158-11-201306040-00007

[22] Coresh, J., Selvin, E., Stevens, L.A., Manzi, J., Kusek, J.W., Eggers, P., et al. (2007) Prevalence of Chronic Kidney Disease in the United States. JAMA, 298, 2038-2047. http://dx.doi.org/10.1001/jama.298.17.2038

[23] Patel, N., Golzy, M., Nainani, N., Nader, N.D., Carter, R.L., Lohr, J.W., et al. (2015) Prevalence of Various Comorbidities among Veterans with Chronic Kidney Disease and Its Comparison with Other Datasets. Renal Failure, 1-5.

[24] Inker, L.A., Astor, B.C., Fox, C.H., Isakova, T., Lash, J.P., Peralta, C.A., et al. (2014) KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 63, 713-735. http://dx.doi.org/10.1053/j.ajkd.2014.01.416

[25] Li, L., Yang, C., Zhao, Y., Zeng, X., Liu, F. and Fu, P. (2014) Is Hyperuricemia an Independent Risk Factor for New-Onset Chronic Kidney Disease?: A Systematic Review and Meta-Analysis Based on Observational Cohort Studies. BMC Nephrology, 15, 122. http://dx.doi.org/10.1186/1471-2369-15-122

[26] Kohagura, K., Kochi, M., Miyagi, T., Kinjyo, T., Maehara, Y., Nagahama, K., et al. (2013) An Association between Uric Acid Levels and Renal Arteriolopathy in Chronic Kidney Disease: A Biopsy-Based Study. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 36, 43-49. http://dx.doi.org/10.1038/hr.2012.135

[27] Madero, M., Sarnak, M.J., Wang, X., Greene, T., Beck, G.J., Kusek, J.W., et al. (2009) Uric Acid and Long-Term Outcomes in CKD. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 53, 796-803. http://dx.doi.org/10.1053/j.ajkd.2008.12.021

[28] Mok, Y., Lee, S.J., Kim, M.S., Cui, W., Moon, Y.M. and Jee, S.H. (2012) Serum Uric Acid and Chronic Kidney Disease: The Severance Cohort study. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association—European Renal Association, 27, 1831-1835. http://dx.doi.org/10.1093/ndt/gfr530

[29] Bellomo, G., Venanzi, S., Verdura, C., Saronio, P., Esposito, A. and Timio, M. (2010) Association of Uric Acid with Change in Kidney Function in Healthy Normotensive Individuals. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 56, 264-272. http://dx.doi.org/10.1053/j.ajkd.2010.01.019

[30] Wang, Y. and Bao, X. (2013) Effects of Uric Acid on Endothelial Dysfunction in Early Chronic Kidney Disease and Its Mechanisms. European Journal of Medical Research, 18, 26. http://dx.doi.org/10.1186/2047-783X-18-26

[31] Pal, P.B., Sinha, K. and Sil, P.C. (2014) Mangiferin Attenuates Diabetic Nephropathy by Inhibiting Oxidative Stress Mediated Signaling Cascade, TNFα Related and Mitochondrial Dependent Apoptotic Pathways in Streptozotocin-In- duced Diabetic Rats. PLoS ONE, 9, e107220. http://dx.doi.org/10.1371/journal.pone.0107220

[32] Liu, C.M., Sun, Y.Z., Sun, J.M., Ma, J.Q. and Cheng, C. (2012) Protective Role of Quercetin against Lead-Induced Inflammatory Response in Rat Kidney through the ROS-Mediated MAPKs and NF-κB Pathway. Biochimica et Biophysica Acta (BBA)-General Subjects, 1820, 1693-1703. http://dx.doi.org/10.1016/j.bbagen.2012.06.011

[33] Zhuang, Y., Feng, Q., Ding, G., Zhao, M., Che, R., Bai, M., et al. (2014) Activation of ERK1/2 by NADPH Oxidase- Originated Reactive Oxygen Species Mediates Uric Acid-Induced Mesangial Cell Proliferation. American Journal of Physiology. Renal Physiology, 307, F396-F406. http://dx.doi.org/10.1152/ajprenal.00565.2013

[34] Zhou, Y., Fang, L., Jiang, L., Wen, P., Cao, H., He, W., et al. (2012) Uric Acid Induces Renal Inflammation via Activating Tubular NF-κB Signaling Pathway. PLoS ONE, 7, e39738. http://dx.doi.org/10.1371/journal.pone.0039738

[35] Lyngdoh, T., Marques-Vidal, P., Paccaud, F., et al. (2011) Elevated Serum Uric Acid Is Associated with High Circulating Inflammatory Cytokines in the Popula-tion-Based Colaus Study. PLoS One, 6, e19901. http://dx.doi.org/10.1371/journal.pone.0019901

[36] Liu, N., Wang, L., Yang, T., Xiong, C., Xu, L., Shi, Y., et al. (2015) EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy. Journal of the American Society of Nephrology, 26, 2716-2729. http://dx.doi.org/10.1681/ASN.2014080793

[37] Li, Y.C., Ding, X.S., Li, H.M., Zhang, Y. and Bao, J. (2014) Role of G Protein-Coupled Estrogen Receptor 1 in Modulating Transforming Growth Factor-Beta Stimulated Mesangial Cell Extracellular Matrix Synthesis and Migration. Molecular and Cellular Endocrinology, 391, 50-59. http://dx.doi.org/10.1016/j.mce.2014.04.014

[38] Verhave, J.C., Bech, A.P., Wetzels, J.F. and Nijenhuis, T. (2015) Hepatocyte Nuclear Factor 1β-Associated Kidney Disease: More than Renal Cysts and Diabetes. Journal of the American Society of Nephrology, 27, 345-353. http://dx.doi.org/10.1681/ASN.2015050544

[39] Nomura, J., Busso, N., Ives, A., Tsujimoto, S., Tamura, M., So, A., et al. (2013) Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK. PLoS ONE, 8, e75527. http://dx.doi.org/10.1371/journal.pone.0075527

[40] Sanchez-Lozada, L.G., Soto, V., Tapia, E., Avila-Casado, C., Sautin, Y.Y., Nakagawa, T., et al. (2008) Role of Oxidative Stress in the Renal Abnormalities Induced by Experimental Hyperuricemia. American Journal of Physiology. Renal Physiology, 295, F1134-F1141. http://dx.doi.org/10.1152/ajprenal.00104.2008

[41] Cheng, L.C., Murugaiyah, V. and Chan, K.L. (2015) In Vitro Xanthine Oxidase Inhibitory Studies of Lippia nodiflora and Isolated Flavonoids and Phenylethanoid Glycosides as Potential Uric Acid-Lowering Agents. Natural Product Communications, 10, 945-948.

[42] Meng, Z.Q., Tang, Z.H., Yan, Y.X., Guo, C.R., Cao, L., Ding, G., et al. (2014) Study on the Anti-Gout Activity of Chlorogenic Acid: Improvement on Hyperuricemia and Gouty Inflammation. The American Journal of Chinese Medicine, 42, 1471-1483. http://dx.doi.org/10.1142/S0192415X1450092X

[43] Mende, C. (2015) Management of Chronic Kidney Disease: The Relationship between Serum Uric Acid and Development of Nephropathy. Advances in Therapy, 32, 1177-1191. http://dx.doi.org/10.1007/s12325-015-0272-7

[44] Miao, Y., Ottenbros, S.A., Laverman, G.D., Brenner, B.M., Cooper, M.E., Parving, H.H., et al. (2011) Effect of a Reduction in Uric Acid on Renal Outcomes during Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension, 58, 2-7. http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.171488

[45] Chino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., et al. (2014) SGLT2 Inhibitor Lowers Serum Uric Acid through Alteration of Uric Acid Transport Activity in Renal Tubule by Increased Glycosuria. Biopharmaceutics & Drug Disposition, 35, 391-404. http://dx.doi.org/10.1002/bdd.1909

[46] Davies, M.J., Trujillo, A., Vijapurkar, U., Damaraju, C.V. and Meininger, G. (2015) Effect of Canagliflozin on Serum Uric Acid in Patients with Type 2 Diabetes Mellitus. Diabetes, Obesity & Metabolism, 17, 426-429. http://dx.doi.org/10.1111/dom.12439

[47] Haring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U.C., et al. (2014) Empagliflozin as Add-On to Metformin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care, 37, 1650-1659. http://dx.doi.org/10.2337/dc13-2105

[48] Kadowaki, D., Sakaguchi, S., Miyamoto, Y., Taguchi, K., Muraya, N., Narita, Y., et al. (2015) Direct Radical Scavenging Activity of Benzbromarone Provides Beneficial Antioxidant Properties for Hyperuricemia Treatment. Biological & Pharmaceutical Bulletin, 38, 487-492. http://dx.doi.org/10.1248/bpb.b14-00514

[49] Chen, L., Lan, Z., Lin, Q., Mi, X., He, Y., Wei, L., et al. (2013) Polydatin Ameliorates Renal Injury by Attenuating Oxidative Stress-Related Inflammatory Responses in Fructose-Induced Urate Nephropathic Mice. Food and Chemical Toxicology, 52, 28-35. http://dx.doi.org/10.1016/j.fct.2012.10.037

[50] Dabbagh, F., Ghoshoon, M.B., Hemmati, S., Zamani, M., Mohkam, M. and Ghasemi, Y. (2015) Engineering Human Urate Oxidase: Towards Reactivating It as an Important Therapeutic Enzyme. Current Pharmaceutical Biotechnology, 17, 141-146. http://dx.doi.org/10.2174/1389201016666150907113055

[51] Fleischmann, R., Kerr, B., Yeh, L.T., Suster, M., Shen, Z., Polvent, E., et al. (2014) Pharmacodynamic, Pharmacokinetic and Tolerability Evaluation of Concomitant Administration of Lesinurad and Febuxostat in Gout Patients with Hyperuricaemia. Rheumatology, 53, 2167-2174. http://dx.doi.org/10.1093/rheumatology/ket487

[52] Jia, L., Xing, J., Ding, Y., Shen, Y., Shi, X., Ren, W., et al. (2013) Hyperuricemia Causes Pancreatic Beta-Cell Death and Dysfunction through NF-κB Signaling Pathway. PLoS ONE, 8, e78284. http://dx.doi.org/10.1371/journal.pone.0078284

[53] Azevedo, V.F., Buiar, P.G., Giovanella, L.H., Severo, C.R. and Carvalho, M. (2014) Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients. International Journal of Rheumatology, 2014, Article ID: 263720. http://dx.doi.org/10.1155/2014/263720